
Julia Rabelo Santos Ferreira
Federal University of Espírito Santo, BrazilTitle: Cutoff point of TyG Index for Metabolic Syndrome in Brazilian Farmers
Abstract
The determination of Insulin Resistance (IR)
requires sophisticated and costly methods, for this
reason the TyG Index was proposed. This was the
first study in Brazil using Metabolic Syndrome
(MetS) as a predictor of IR in a rural Brazilian
population. The TyG index was calculated: Ln
[fasting triglycerides (mg/dL) x fasting glycemia
(mg/dL)]/2, and MetS was defined using the
NCEP-ATPIII and IDF criteria. For association
analysis, the Mann-Whitney U test was used and
the comparison between means was made using the
Kruskal-Wallis test. For correlations, Spearman's
correlation test was used. The cutoff values of TyG
Index for MetS were obtained using the Receiver
Operating Characteristic (ROC) curve analysis
with the area under the curve (AUC) and the
Youden Index. The median TyG values were
higher among individuals diagnosed with MetS
(p<0.001), and increased according to the
aggregation of the components of MetS. All MetS
components were correlated with TyG (p<0.001).
The AUC for NCEP was 0.873 (0.848-0.896;
p<0.001), with Youden's cutoff point of Ln 4.52
(sensitivity: 84.30%; specificity: 75.75%). The
AUC for IDF was 0.867 (0.842-0.890; p<0.001),
with Youden's cutoff point of Ln 4.55 (sensitivity:
80.0%; specificity: 79.82%). A cutoff point of Ln
4.52 was defined.
In conclusion, the TyG Index is a reliable marker
for identifying insulin-resistant individuals, and
correlates with the metabolic changes present in
MetS. A cutoff point of Ln 4,52 has good
sensitivity and specificity in both diagnostic
criteria of MetS, being useful both in clinical
practice and epidemiological studies, and can
represent an important tool for the creation of
protocols for promotion, protection and recovery
health of rural populations.
Biography
Graduated in Nutrition and Master in Public Health
from the Federal University of Espírito Santo
(UFES). Works as a clinical research nutritionist on
two clinical trials for Eli Lilly Company (A Study
of Tirzepatide (LY3298176) In Participants After
A Lifestyle Weight Loss Program (SURMOUNT-3) and A Study of Tirzepatide (LY3298176) in
Participants With Obesity or Overweight for the
Maintenance of Weight Loss (SURMOUNT-4)), at
the Osteoporosis Diagnosis and Research Center of
Espírito Santo (CEDOES). She is currently
studying Statistics at UFES. At the age of 25, she
has already published two articles using statistical
methodologies unpublished in Brazil, contributed
to the writing of a book chapter and was invited to
carry out several statistical analyzes in the area of
epidemiology, in addition to presenting summaries
of all the articles written so far at national and
global conferences.